跳至主要内容
临床试验/NCT05989984
NCT05989984已完成不适用

Monocentric, Prospective, Randomized Study to Evaluate the Efficacy of a New Iron Supplement with Orodispersible Formulation Vs an Iron Supplement in Capsules in Subjects with Mild Anemia

IBSA Farmaceutici Italia Srl2 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2023年7月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
23
试验地点
2
主要终点
Change from baseline in blood concentration of hemoglobin with ODF iron supplement (test product)

研究概览

简要总结

The aim of the study is to evaluate the efficacy of a new iron supplement with orodispersible formulation vs an iron supplement in capsules in subjects with mild anemia.

详细描述

The aim of the study is to evaluate the efficacy of a new iron supplement with orodispersible formulation in modulating peripheral blood biomarkers of iron levels in subjects with mild anemia after 8 weeks of supplementation, compared to baseline values and also aims to evaluate its acceptability. For the evaluation, an iron supplement in capsules will be used as a comparison supplement.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

盲法说明

No masking procedure will be applied

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Written informed consent signed prior to inclusion in the study
  • 18-55 years
  • Ability to understand the nature and the purpose of the study, including possible risks and side effects
  • Capability to collaborate with the investigator and meet the requirements of the entire study
  • Subjects with mild anemia (with WHO hemoglobin values between 11-11.9 g/dl for women and between 11-12.9 g/dl for men)

排除标准

  • Clinically significant abnormalities in the ECG evaluation
  • Clinically significant abnormal laboratory values indicative of disease
  • Known allergy or presumed hypersensitivity to the food supplement investigated (iron) and / or to the excipients of the two formulations
  • History of anaphylaxis from drugs, dietary supplements or allergic reactions in general, which the investigator believed could influence the outcome of the study
  • Significant history of kidney, liver, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the purpose of the study
  • Taking herbal remedies and dietary supplements (including iron supplements, supplements with vitamin C, supplements with folic acid, supplements with vitamin B12, multivitamins) in the 2 weeks prior to the start of the study
  • Taking corticosteroids, thyroid hormones, antibiotics, antiepileptics
  • Alcohol abuse
  • Any clinical condition that in the investigator's judgment is deemed incompatible with study participation
  • Women who are pregnant or breastfeeding

结局指标

主要结局

Change from baseline in blood concentration of hemoglobin with ODF iron supplement (test product)

时间窗: Day 0, Week 8

Change from baseline in blood concentration of hemoglobin after 8 weeks of supplementation with ODF iron supplement

次要结局

  • Change from baseline in blood concentration of transferrin(Day 0, Week4, Week 8)
  • Change from baseline in mean corpuscolar volume (MCV)(Day 0, Week4, Week 8)
  • Change from baseline in blood concentration of ferritin(Day 0, Week4, Week 8)
  • Change from baseline in blood concentration of hemoglobin with test product(Day 0, Week 4)
  • Change from baseline in blood concentration of transferrin receptor(Day 0, Week4, Week 8)
  • Change from baseline in blood concentration of folic acid(Day 0, Week4, Week 8)
  • Change from baseline in blood concentration of serum iron(Day 0, Week4, Week 8)
  • Change from baseline in blood concentration of hemoglobin with Iron supplement in capsule (reference product)(Day 0, Week4, Week 8)
  • Change from baseline in blood concentration of hematocrit(Day 0, Week4, Week 8)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验